BREAKING
Nexxen Q4 FY26 Earnings Results 6 hours ago Daktronics Q3 FY26 Earnings Results 7 hours ago Earnings Summary: SmartRent Returns to Growth in Q4FY25, Achieves Positive EBITDA. 9 hours ago Abercrombie & Fitch Q4 2025 Earnings Results 10 hours ago AutoZone (AZO) Q2 2026 earnings decline despite 8% sales growth 1 day ago Best Buy 4Q 2026: Earnings Analysis 1 day ago Earnings Summary: Zymeworks (ZYME) Q4 FY25 net loss widens 2 days ago Earnings Summary: A snapshot of Smith+Nephew’s (SNN) Q4 2025 report 2 days ago Earnings Summary: Norwegian Cruise Line (NCLH) Q4 FY25 revenue rises 6% 2 days ago Earnings Summary: Highlights of Calumet’s (CLMT) Q4 2025 earnings report 5 days ago Nexxen Q4 FY26 Earnings Results 6 hours ago Daktronics Q3 FY26 Earnings Results 7 hours ago Earnings Summary: SmartRent Returns to Growth in Q4FY25, Achieves Positive EBITDA. 9 hours ago Abercrombie & Fitch Q4 2025 Earnings Results 10 hours ago AutoZone (AZO) Q2 2026 earnings decline despite 8% sales growth 1 day ago Best Buy 4Q 2026: Earnings Analysis 1 day ago Earnings Summary: Zymeworks (ZYME) Q4 FY25 net loss widens 2 days ago Earnings Summary: A snapshot of Smith+Nephew’s (SNN) Q4 2025 report 2 days ago Earnings Summary: Norwegian Cruise Line (NCLH) Q4 FY25 revenue rises 6% 2 days ago Earnings Summary: Highlights of Calumet’s (CLMT) Q4 2025 earnings report 5 days ago
ADVERTISEMENT
Market News

Gilead Sciences Q3 2023 Earnings: Stay tuned for the live earnings call and real-time transcript

Gilead Sciences, Inc. (NASDAQ: GILD), a leading research-based biopharmaceutical company, will be reporting third-quarter results today at 4:00 p.m. ET. Listen to Gilead Sciences‘ earnings call live and check the real-time transcript Analysts’ consensus estimate for September-quarter earnings is $1.81 per share, on an adjusted basis, which marks a decline from $1.90 per share the […]

November 7, 2023 1 min read

Gilead Sciences, Inc. (NASDAQ: GILD), a leading research-based biopharmaceutical company, will be reporting third-quarter results today at 4:00 p.m. ET. Listen to Gilead Sciences‘ earnings call live and check the real-time transcript Analysts’ consensus estimate for September-quarter earnings is $1.81 per share, on an adjusted basis, which marks a decline from $1.90 per share the […]

· November 7, 2023

Gilead Sciences, Inc. (NASDAQ: GILD), a leading research-based biopharmaceutical company, will be reporting third-quarter results today at 4:00 p.m. ET.

Listen to Gilead Sciences earnings call live and check the real-time transcript



Analysts’ consensus estimate for September-quarter earnings is $1.81 per share, on an adjusted basis, which marks a decline from $1.90 per share the company earned in the year-ago quarter. Revenue is expected to be $6.42 billion, up 4.8% year-over-year.

For the second quarter, the company reported total revenue of $6.6 billion, which is up 5% year-over-year. Net income attributable to Gilead was $1 billion or $0.83 per share in Q2, compared to $1.1 billion, or $0.91 per share last year. Adjusted EPS decreased 15% to $1.34.